Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development

doi:10.4252/wjsc.v16.i10.860

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1380)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

HTML

864

Figures (1-4)

Tables (1-2)

Sum=1054

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=165

Publishing Process of This Article

Item

Count

Browse

Download

Sum=120

Oct 26, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Oct 26, 2024; 16(10): 860-872
Published online Oct 26, 2024. doi: 10.4252/wjsc.v16.i10.860

Full Size Figure Download Figure

Figure 1 Three main types of advanced therapy medicinal products. Non-advanced therapeutic products are regulated separately from advanced therapeutic products and may be used in combination with advanced therapeutic products. ATPs: Advanced therapeutic products; cATMP: Combined advanced therapy medicinal product; SCTM: Somatic cell therapy medicine; GTMP: Gene therapy medicinal product; TEP: Tissue-engineered products; iPSC: Induced pluripotent stem cell; MSC: Mesenchymal stem cell; CRISPR/Cas9: Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9; CAR-T: Chimeric antigen receptor T; 3D: Three-dimensional.

Citation: Granjeiro JM, Borchio PGM, Ribeiro IPB, Paiva KBS. Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development. World J Stem Cells 2024; 16(10): 860-872
URL: https://www.wjgnet.com/1948-0210/full/v16/i10/860.htm
DOI: https://dx.doi.org/10.4252/wjsc.v16.i10.860